{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:59:39Z","timestamp":1794851979501,"version":"4.9.1"},"reference-count":89,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Liver fibrosis results from repeated and persistent liver damage. It can start with hepatocyte injury and advance to inflammation, which recruits and activates additional liver immune cells, leading to the activation of the hepatic stellate cells (HSCs). It is the primary source of myofibroblasts (MFs), which result in collagen synthesis and extracellular matrix protein accumulation. Although there is no FDA and EMA-approved anti-fibrotic drug, antiviral therapy has made remarkable progress in preventing or even reversing the progression of liver fibrosis, but such a strategy remains elusive for patients with viral, alcoholic or nonalcoholic steatosis, genetic or autoimmune liver disease. Due to the complexity of the etiology, combination treatments affecting two or more targets are likely to be required. Here, we review the pathogenic mechanisms of liver fibrosis and signaling pathways involved, as well as various molecular targets for liver fibrosis treatment. The development of efficient drug delivery systems that target different cells in liver fibrosis therapy is also summarized. We highlight promising anti-fibrotic events in clinical trial and preclinical testing, which include small molecules and natural compounds. Last, we discuss the challenges and opportunities in developing anti-fibrotic therapies.<\/jats:p>","DOI":"10.3390\/ijms232012572","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T22:49:46Z","timestamp":1666306186000},"page":"12572","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["The Molecular Mechanisms of Liver Fibrosis and Its Potential Therapy in Application"],"prefix":"10.3390","volume":"23","author":[{"given":"Danyan","family":"Zhang","sequence":"first","affiliation":[{"name":"School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China"},{"name":"State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaguang","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, Shanghai Tech University, Shanghai 201210, China"},{"name":"State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6866","DOI":"10.1166\/jnn.2019.16936","article-title":"Sorafenib-Loaded Ligand-Functionalized Polymer-Lipid Hybrid Nanoparticles for Enhanced Therapeutic Effect Against Liver Cancer","volume":"19","author":"Tang","year":"2019","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"F1000 Faculty Rev-921","DOI":"10.12688\/f1000research.14841.1","article-title":"Recent advances in understanding liver fibrosis: Bridging basic science and individualized treatment concepts","volume":"7","author":"Weiskirchen","year":"2018","journal-title":"F1000Research"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jconrel.2018.09.004","article-title":"Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis","volume":"288","author":"Kurniawan","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","article-title":"Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues","volume":"65","author":"Parola","year":"2019","journal-title":"Mol. Aspects Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12951-020-00645-y","article-title":"Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy","volume":"18","author":"Ji","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Thomas, R.G., Moon, M.J., Kim, J.H., Lee, J.H., and Jeong, Y.Y. (2015). Effectiveness of Losartan-Loaded Hyaluronic Acid (HA) Micelles for the Reduction of Advanced Hepatic Fibrosis in C3H\/HeN Mice Model. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145512"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.matbio.2018.04.006","article-title":"Liver fibrosis: Direct antifibrotic agents and targeted therapies","volume":"68","author":"Schuppan","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.nano.2017.11.004","article-title":"Cell type-specific pharmacological kinase inhibition for cancer chemoprevention","volume":"14","author":"Deshmukh","year":"2018","journal-title":"Nanomedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: Physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1021\/acsnano.9b06071","article-title":"Rapid Intestinal Uptake and Targeted Delivery to the Liver Endothelium Using Orally Administered Silver Sulfide Quantum Dots","volume":"14","author":"Hunt","year":"2020","journal-title":"ACS Nano"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/febs.13665","article-title":"TGF-b signalling and liver disease","volume":"283","author":"Fabregat","year":"2016","journal-title":"FEBS J."},{"key":"ref_19","first-page":"28","article-title":"Thrombospondin-1 regulation of latent TGF-b activation: A therapeutic target for fibrotic disease","volume":"68","author":"Suto","year":"2018","journal-title":"Matrix Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1053\/j.gastro.2019.07.036","article-title":"ECM1 Prevents Activation of Transforming Growth Factor b, Hepatic Stellate Cells, and Fibrogenesis in Mice","volume":"157","author":"Fan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_21","first-page":"960","article-title":"Targeting the Wnt Signaling Pathway in Liver Fibrosis for Drug Options: An Update","volume":"9","author":"Duspara","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","article-title":"Inhibition of canonical WNT signaling pathway by b-catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12","volume":"1864","author":"Akcora","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/ptr.6824","article-title":"Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3b and suppression of Wnt\/b-catenin pathway in hepatic stellate cells","volume":"35","author":"Lee","year":"2021","journal-title":"Phytother. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2010.10.003","article-title":"Hedgehog signaling in the liver","volume":"54","author":"Omenetti","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.04.022","article-title":"An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis","volume":"303","author":"Li","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2021.11.005","article-title":"Liquid biomarkers for fibrotic NASH\u2014Progress in a complex field","volume":"76","author":"Schuppan","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled Phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100255","DOI":"10.1016\/j.jhepr.2021.100255","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): An investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, Phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, Phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated with Nonalcoholic Steatohepatitis and Fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11883-015-0500-2","article-title":"FXR agonists as therapeutic agents for non-alcoholic fatty liver disease","volume":"17","author":"Carr","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)","volume":"24","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a Nonsteroidal FXR Agonist, in Patients with Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications\u2014A review","volume":"13","year":"2014","journal-title":"Nutr. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1440-1746.2004.03562.x","article-title":"Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease","volume":"19","author":"Macdonald","year":"2004","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2016-312431","article-title":"Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease","volume":"66","author":"Rotman","year":"2017","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chen, J., Montagner, A., Tan, N.S., and Wahli, W. (2018). Insights into the Role of PPARb\/d in NAFLD. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071893"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-a and -d, Induces Resolution of Nonalcoholic Steatohepatitis without Fibrosis Worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2337\/dc12-2012","article-title":"Dual peroxisome proliferator-activated receptor a\/d agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects","volume":"36","author":"Cariou","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106174","DOI":"10.1016\/j.cct.2020.106174","article-title":"Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers","volume":"97","author":"Harrison","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"28992","DOI":"10.1073\/pnas.2012073117","article-title":"Antibody-mediated activation of the FGFR1\/Klothobeta complex corrects metabolic dysfunction and alters food preference in obese humans","volume":"117","author":"Baruch","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41419-020-03261-8","article-title":"Hepatocyte cannabinoid 1 receptor nullification alleviates toxin-induced liver damage via NF-kB signaling","volume":"11","author":"Kim","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.jhepr.2019.100064","article-title":"A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage","volume":"2","author":"Barashi","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.cgh.2017.04.016","article-title":"A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis","volume":"15","author":"Kheong","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e9061","DOI":"10.1097\/MD.0000000000009061","article-title":"The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials","volume":"96","author":"Zhong","year":"2017","journal-title":"Medicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"111092","DOI":"10.1016\/j.nut.2020.111092","article-title":"Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"83","author":"Kalopitas","year":"2021","journal-title":"Nutrition"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1158\/1078-0432.CCR-18-3358","article-title":"Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells","volume":"25","author":"Wu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0968-0004(06)80023-X","article-title":"Hsp47: A collagen-specific molecular chaperone","volume":"21","author":"Nagata","year":"1996","journal-title":"Trends Biochem. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.21037\/atm.2020.02.119","article-title":"Mesenchymal stem cell therapy for liver fibrosis\/cirrhosis","volume":"8","author":"Cao","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41420-022-00846-4","article-title":"ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF-b\/Smad signaling pathway","volume":"8","author":"Liu","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpdd.782","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver-Targeting Acetyl-CoA Carboxylase Inhibitor (PF-05221304): A Three-Part Randomized Phase 1 Study","volume":"9","author":"Bergman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1021\/acs.jmedchem.0c00640","article-title":"Optimizing the Benefit\/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting","volume":"63","author":"Huard","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/cpdd.762","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers","volume":"9","author":"Badman","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Robert","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPARa\/g agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: Integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Honda, Y., Imajo, K., Kato, T., Kessoku, T., Ogawa, Y., Tomeno, W., Kato, S., Mawatari, H., Fujita, K., and Yoneda, M. (2016). The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146337"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., Chou, H.L., Hashiguchi, T., Plato, C., and Poulin, D. (2016). Antifibrotic Effects of the Dual CCR2\/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158156"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/13543784.2018.1494153","article-title":"MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis","volume":"27","author":"Colca","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exger.2015.02.004","article-title":"Anti-inflammatory effect of resveratrol in old mice liver","volume":"64","author":"Tung","year":"2015","journal-title":"Exp. Gerontol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2174\/092986707782360169","article-title":"Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases","volume":"14","author":"Yoshiji","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jhep.2005.02.034","article-title":"Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice","volume":"43","author":"Yang","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fphar.2015.00300","article-title":"New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials","volume":"6","author":"Qu","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/hep.22758","article-title":"Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats","volume":"49","author":"Mejias","year":"2009","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2018.07.006","article-title":"Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis","volume":"155","author":"Harrison","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/20\/12572\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:57:46Z","timestamp":1760144266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/20\/12572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":89,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms232012572"],"URL":"https:\/\/doi.org\/10.3390\/ijms232012572","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}